Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699325 | 1.00 | P2RX7 (0.51) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL2373230 | 0.77 | HDAC4 (0.41) | KDM4EHDAC6HDAC8HTR2A | |
| SCHEMBL17707609 | 0.70 | P2RX7 (0.55) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL27906099 | 0.69 | P2RX7 (0.66) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| Trifluoroacetic Acid SCHEMBL2202389 | 0.68 | P2RX7 (0.53) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL24333460 | 0.68 | P2RX7 (0.64) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL18913834 | 0.68 | P2RX7 (0.64) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL24333207 | 0.68 | P2RX7 (0.64) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL4469167 | 0.67 | SLC6A7 (0.55) | P2RX7HSP90AA1KDM4EALDH1A1PKM | |
| SCHEMBL4650203 | 0.67 | P2RX7 (0.51) | P2RX7HSP90AA1KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-11-06 | — | — | US | disclosed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | disclosed |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-9365552-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8476269-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | P2RX7 39/4885HSP90AA1 3785/4885KDM4E 2343/4885 |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | P2RX7 38/4885HSP90AA1 3462/4885KDM4E 1465/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | P2RX7 39/4885HSP90AA1 3785/4885KDM4E 2343/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | P2RX7 35/4885HSP90AA1 3744/4885KDM4E 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.